Fu X R, Wan W J, Sun Z C, Zhang X D, Nan F F, Ge J R, Xia Y Q, Zhang M Z
Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou 450052, China.
Zhonghua Xue Ye Xue Za Zhi. 2020 Nov 14;41(11):921-926. doi: 10.3760/cma.j.issn.0253-2727.2020.11.007.
To analysis the expression of CD7 in NK/T-cell lymphoma as well as study the correlations between CD7 and clinical survival and prognosis. The clinical and pathological indicators of 112 NKTCL patients who were admitted to or consulted at the First Affiliated Hospital of Zhengzhou University between May 2008 and December 2019 were analyzed retrospectively. The CD7 expression in the tumor tissues was detected using immunohistochemistry staining, and the influence of CD7 expression on the survival and prognosis in the patients was analyzed. The CD7 expression rate was 84.82% in 112 NKTCL patients, and its expression was not influenced by sex, age, and the primary site. An analysis of the complete clinical data of 72 patients showed that the CD7 expression was significantly correlated with the PINK score, tumor metastasis, and peripheral blood EBV-DNA level. However, the Ann Arbor stage, bone marrow involvement, B symptoms, IPI/aaIPI score, Ki-67, EBER, TIA-1, Granzyme B, LDH, and β(2)-MG were not associated with the CD7 expression. The 1-year, 3-year, and 5-year overall survival (OS) rates of the 72 patients were 81.2%, 61.8%, and 58.8%, respectively, and the progression-free survival (PFS) rates were 53.5%, 29.4%, and 24.0%, respectively. The median overall survival (median-OS, mOS) was 81 mon, and the median progression-free survival (median-PFS, mPFS) was 14 mon. The 3-year OS rates in the CD7-positive group and the CD7-negative group were 58.1% and 83.9%, respectively, (>0.05) . The 3-year PFS rates were 21.7% and 51.9%, respectively (<0.05) . The univariate analysis showed that age, primary tumor site, Ann Arbor stage, IPI/aaIPI score, PINK score, LDH, β(2)-microglobulin, EBV-DNA, Ki-67, and CD7 influenced patient prognosis. The multivariate analysis showed that Ann Arbor stage and CD7 were independent prognostic factors for PFS, while PINK score and Ki-67 were independent prognostic factors for OS. The expression rate of CD7 in NKTCL was high and was closely related to poor patient prognosis. The patients with high levels of EBV-DNA, metastatic disease, or high PINK score were more likely to express CD7.
分析CD7在NK/T细胞淋巴瘤中的表达情况,并研究CD7与临床生存及预后之间的相关性。回顾性分析2008年5月至2019年12月在郑州大学第一附属医院收治或会诊的112例NKTCL患者的临床和病理指标。采用免疫组织化学染色检测肿瘤组织中CD7的表达,并分析CD7表达对患者生存及预后的影响。112例NKTCL患者中CD7表达率为84.82%,其表达不受性别、年龄及原发部位的影响。对72例患者的完整临床资料分析显示,CD7表达与PINK评分、肿瘤转移及外周血EBV-DNA水平显著相关。然而,Ann Arbor分期、骨髓受累、B症状、IPI/aaIPI评分、Ki-67、EBER、TIA-1、颗粒酶B、LDH及β2-微球蛋白与CD7表达无关。72例患者的1年、3年和5年总生存率(OS)分别为81.2%、61.8%和58.8%,无进展生存率(PFS)分别为53.5%、29.4%和24.0%。中位总生存时间(median-OS,mOS)为81个月,中位无进展生存时间(median-PFS,mPFS)为14个月。CD7阳性组和CD7阴性组的3年OS率分别为58.1%和83.9%(>0.05)。3年PFS率分别为21.7%和51.9%(<0.05)。单因素分析显示,年龄、原发肿瘤部位、Ann Arbor分期、IPI/aaIPI评分、PINK评分、LDH、β2-微球蛋白、EBV-DNA、Ki-67及CD7影响患者预后。多因素分析显示,Ann Arbor分期和CD7是PFS的独立预后因素,而PINK评分和Ki-67是OS的独立预后因素。NKTCL中CD7表达率较高,且与患者预后不良密切相关。EBV-DNA水平高、有转移或PINK评分高的患者更易表达CD7。